Equol, a powerful estrogen-like compound derived from soy, could be key to better health in postmenopausal women if gut microbiome could be altered to facilitate its production.
The methodology of this research involved looking closely at the properties and actions of equol, a metabolite of the soy isoflavone daidzein. This substance is produced through the process of intestinal bacterial metabolism, but the ability to produce it is not present in over half of the human population due to the absence of specific equol-producing bacteria in the gastrointestinal tract. Given that the make up of the gut microbiome varies from person to person, understanding the effects of equol and daidzein in the human body has been a complex task. Furthermore, the fact that rodents easily produce equol complicates the matter, as findings from rodent models may not directly apply to humans.
While interpreting the results, it was found that equol, due to its strong estrogenic activity, could potentially be an excellent means to manage postmenopausal symptoms and overall health. However, the ability to produce equol varies significantly among people, based on the bacterial microflora of their gut. Therefore, the benefits of equol could potentially be amplified by finding effective methods to manipulate the gut microbiome to foster equol production, a strategy that could lead to improved health outcomes for postmenopausal women.
